Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Chen, Ingrid T ^a   Aung, Tin ^b   Thant, Hnin Nwe Nwe ^b   Sudhinaraset, May ^a   Kahn, James G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b POPULATION SERVICES INTERNATIONAL   (United States)

Author keywords

Artemisinin combination therapy; Behaviour communication change; Cost effectiveness; Drug resistance; Informal provider; Malaria; Myanmar; Rapid diagnostic test; Subsidy

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; FEVER; FINANCIAL INCENTIVE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA RAPID TEST; MEDICAL INFORMATION; MYANMAR; PATIENT COUNSELING; PILOT STUDY; PRIVATE PRACTICE; REWARD; COST BENEFIT ANALYSIS; ECONOMICS; PARASITOLOGY; PERSONNEL MANAGEMENT; PRIVATE SECTOR; PROCEDURES;

COST-BENEFIT ANALYSIS; DECISION TREES; HEALTH PERSONNEL; HUMANS; MALARIA; MYANMAR; PARASITOLOGY; PHYSICIAN INCENTIVE PLANS; PRIVATE SECTOR;

EID: 84928712745     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0569-7     Document Type: Article

References (47)

1. Lin JT, Julaino JJ, Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep. 2010;12:165-73.
2. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272-80.
3. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;279:1960-6.
4. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48:4075-83.
5. Greenwood BM, Bojang K, Whitty CJM, Targett GA. Malaria. Lancet. 2004;365:1497-8.
6. WHO. World Malaria Report 2011. World Health Organization, Geneva. [http://www.who.int/malaria/world-malaria-report-2011/en/]
7. WHO. Malaria Country Profiles 2014, Myanmar. [http://www.who.int/malaria/publications/country-profiles/profile-mmr-en.pdf]
8. Center for Disease Control and Prevention. Health Information for Travelers to Burma (Myanmar). [http://wwwnc.cdc.gov/travel/destinations/burma.htm]
9. Population Services International Myanmar: Improving Health in Myanmar. [http://www.psi.org/myanmar]
10. Relief web. Union Minister: Malaria cases, death rate down in Myanmar. [http://reliefweb.int/report/myanmar/union-minister-malaria-cases-deathratedown-myanmar]
11. WHO. World Malaria Report 2008. World Health Organization, Geneva. [http://www.who.int/malaria/publications/atoz/9789241563697/en/]
12. Schlein K, Drasser K, Montagu D. Clinical Social Franchising Case Study Series. Sun Quality Health, Population Services International/Myanmar. San Francisco: The Global Health Group, Global Health Sciences, University of California, San Francisco. 2010
13. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010 World Health Organization, Geneva. [http://whqlibdoc.who.int/publications/2010/9789241500470-eng.pdf]
14. Newton P, Proux S, Green M, Smithuis F, Rozendaal J, Prakongpan J, et al. Fake artesunate in southeast Asia. Lancet. 2001;357:1948-50.
15. Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health. 2004;9:1241-6.
16. Newton PN, Fernández FM, Plançon A, Mildenhall DC, Green MD, Ziyong L, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in south east Asia. PLoS Med. 2008;5:209-19.
17. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Brunteon C, et al. Manslaughter by fake artesunate in Asia - will Africa be next? PLoS Med. 2006;3:e197.
18. WHO. Global plan for artemisinin resistance containment. World Health Organization, Geneva. [http://www.who.int/malaria/publications/atoz/artemisinin-resistance-containment-2011.pdf]
19. World Health Organization. T3. Test. Treat. Track. [http://www.who.int/malaria/publications/atoz/test-treat-track-brochure.pdf]
20. Yeung S, Patouillard E, Allen H, Socheat D. Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J. 2011;10:243.
21. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transition: 2002-2030. Ann Trop Med Parasitol. 2006;100:481-99.
22. Murray CJL, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, et al. Global burden of disease 2005: call for collaborators. Lancet. 2007;370:109-10.
23. WHO. SEARO 2006. [http://www.who.int/malaria/publications/countryprofiles/2008/mal2008-myanmar-en.pdf]
24. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, Guthmann JP, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother. 2004;48:4271-80.
25. Ohnmar TM, May-Aye-Than, San-Shwe, Wai-Wai-Mying, Chongsuvivatwong V. Access to a blood test and antimalarials after introducing rapid diagnostic tests in rural Myanmar: initial experience in a malaria endemic area. Int Health. 2010, 2:275-281
26. Richards AK, Banek K, Mullany LC, Lee CI, Smith L, Oo EK, et al. Cross-border malaria control for internally displaced persons: observational results from a pilot programme in eastern Burma/Myanmar. Trop Med Int Health. 2009;14:512-21.
27. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;5:430-5.
28. Tijtra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua. Indonesia PLoS Med. 2008;5:e128.
29. WHO. Global Burden of Disease Death Estimates 2008. World Health Organization, Geneva. [http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/index.html]
30. Mayxay M, Castonguay-Vanier J, Chansamouth V, Dubot-Pérès A, Paris DH, Phetsouvanh Tangkhabuanbutra J, et al. Causes of non-malarial fever in Laos: a prospective study. Lancet. 2013;1:46-54.
31. Ejov MN, Tun T, Aung S, Lwi S, Sein K. Hospital-based study of severe malaria and associated deaths in Myanmar. Bull World Health Organ. 1999;77:4.
32. World Bank. Myanmar. [http://data.worldbank.org/country/myanmar]
33. Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, et al. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study. Lancet. 2013;380:2144-62.
34. Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, Levin-Rector A, et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2071-94.
35. Foundation of Innovative New Diagnostics. [http://www.finddiagnostics.org/resource-centre/reports-brochures/malaria-diagnostic-test-report.html]
36. Shillcutt S, Morel C, Goodman C, Coleman P, Bell D, Whitty CJ, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ. 2008;86:101-10.
37. Cohen J, Fink G, Berg K, Aber F, Jordan M, Maloney K, et al. Feasibility of distributing rapid diagnostic tests for malaria in the retail sector: evidence from an implementation study in Uganda. PLoS One. 2012;7:e48296.
38. Ohnmar TM, San-Shwe, Than-Win, Chongsuvivatwong V. Effects of malaria volunteer training on coverage and timeliness of diagnosis: a cluster randomized controlled trial in Myanmar. Malar J. 2012;11:309
39. Cho-Min-Naing, Gatton ML. Costs to the patient for seeking malaria care in Myanmar. Acta Trop. 2004;92:173-177
40. WHO. Emergency response to artemisinin response in the Greater Mekong Subregion. Regional framework for action. 2013-2015 [http://apps.who.int/iris/bitstream/10665/79940/1/9789241505321-eng.pdf?ua=1]
41. Wiwanitkit V. High prevalence of malaria in Myanmar migrant workers in a rural district near the Thai-Myanmar border. Scand J Infect Dis. 2002;34:236-7.
42. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun. 2012;3:1237.
43. Lawpoolsri S, Chavez IF, Yimsamran S, Puangsa-Art S, Thanyavanich N, Maneeboonyang W, et al. The impact of human reservoir of malaria at a community-level on individual malaria occurrence in a low malaria transmission setting along the Thai-Myanmar border. Malar J. 2010;9:143.
44. Mosha JF, Sturrock HJ, Greenhouse B, Greenwood B, Sutherland CJ, Gadalla N, et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar J. 2013;12:221.
45. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382:900-11.
46. Bastiaens GJH, Bousema T, Leslie TL. Scale-up of malaria rapid diagnostic tests and artemisinin-based combination therapy: challenges and perspectives in sub-Saharan Africa. PLoS Med. 2014;11:e1001590.
47. Morris U, Aydin-Schmidt B, Shakely D, Mårtensson A, Jörnhagen L, Ali AS, et al. Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria-assessment of DNA extraction methods and field applicability. Malar J. 2013;12:106.